The Edge Provided by Prostratin Utilization in Reversing Latency and Eradicating Human Immunodeficiency Virus The Application of Medicinal Plant Extract to Overcome Latency and Eradicate Human Immunodeficiency Virus Completely

Main Article Content

Nadine Aurelie


Background: For decades, HIV has caused severe impact toward society by generating vulnerable population. Even though this condition can be kept stabile with antiretroviral usage, other issues including toxicity and resistance emerge due to long term utilization. Therefore, researchers have taken new approach to eradicate HIV infection, which is through shock and kill pace using latency reversal agent. One of the promising candidates is prostratin, compound obtained from medicinal plant extract.

Discussion: Aside of reactivating latent HIV-infected cell, prostratin can also prepare related immune system function to combat and eliminate HIV infection, enhancing success chance to obtain full recovery. Combination alongside with other pharmacotherapy agents can further escalate synergist effectivity in shock and kill approach, thus maximizing eradication of HIV infection completely.

Conclusion: Therefore, based on the discussion that has been explained above, it can be sum up that prostratin has several advantages compared to other latency reversal agents. Thus, prostratin application might bring one step closer for mankind to annihilate HIV infection completely.

Article Details

How to Cite
Aurelie, N. (2022). The Edge Provided by Prostratin Utilization in Reversing Latency and Eradicating Human Immunodeficiency Virus. JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia, 10(1), 109-113.


1. Margolis DM, Garcia JV, Hazuda DJ, Haynes BF. Latency reversal and viral clearance to cure HIV-1. Science. 2016; 353(6297): aaf6517.
2. Spivak AM, Planelles V. Novel latency reversal agents for HIV-1 cure.
3. Desimio MG, Giuliani E, Ferraro AS, Adorno G, Doria M. In vitro exposure to prostratin but not bryostatin-1 improves natural killer cell functions including killing of CD4+T cells harboring reactivated Human Immunodeficiency Virus. Front Immunol. 2018; 9: 1514.
4. Ait-Ammar A, Kula A, Darcis G, Verdikt R, De Wit S, Gautier V. Current status of latency reversing agents facing the heterogeneity of HIV-1 cellular and tissue reservoirs. Front Microbiol. 2020; 10: 3060.
5. Cragg GM, Newman DJ, Kingston DGI. Comprehensive natural products II. Vol. 2, Natural products structural diversity-II secondary metabolites: Sources, structures, and chemical biology. Amsterdam: Elsevier; 2010. Chapter 2, Terrestrial plants as a source of novel pharmaceutical agents; p.5-39.
6. Grau-Exposito J, Luque-Ballesteros L, Navarro J, Curran A, Burgos J, Ribera E, et al. Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations. PLoS Pathog. 2019; 15(8): e1007991.
7. Beans EJ, Fournogerakis D, Gauntlett C, Heumann LV, Kramer R, Marsden MD, et al. Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo. Proc Natl Acad Sci USA. 2013; 110(29): 11698-703.
8. Wender PA, Kee J, Warrington JM. Practical synthesis of prostratin, DPP, and their analogs, adjuvant leads against latent HIV. Science. 2008; 320(5876): 649-52.